公开(公告)号：WO2010102251A2

公开(公告)日：2010-09-10

申请号：PCT/US2010/026424

申请日：2010-03-05

Applicant: ABBOTT LABORATORIES ,  HSIEH, Chung-Ming ,  HUGUNIN, Margaret ,  MURTAZA, Anwar ,  McRAE, Bradford, L. ,  KUTSKOVA, Yuliya ,  MEMMOTT, John, E. ,  PEREZ, Jennifer, M. ,  ZHONG, Suju ,  TARCSA, Edit ,  CLABBERS, Anca ,  WALLACE, Craig ,  BRYANT, Shaughn, H. ,  LEDDY, Mary, R.

Inventor： HSIEH, Chung-Ming ,  HUGUNIN, Margaret ,  MURTAZA, Anwar ,  McRAE, Bradford, L. ,  KUTSKOVA, Yuliya ,  MEMMOTT, John, E. ,  PEREZ, Jennifer, M. ,  ZHONG, Suju ,  TARCSA, Edit ,  CLABBERS, Anca ,  WALLACE, Craig ,  BRYANT, Shaughn, H. ,  LEDDY, Mary, R.

IPC: A61K39/395

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2300/00 ,  C07K16/241 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466

Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Abstract translation: 与用于治疗，预防和诊断IL-17相关疾病和检测细胞，组织，样品和组合物中的IL-17的组合物和方法一起描述了结合IL-17和/或IL-17F的蛋白质。

公开(公告)号：WO2010102251A3

公开(公告)日：2010-11-25

申请号：PCT/US2010026424

申请日：2010-03-05

Applicant: ABBOTT LAB ,  HSIEH CHUNG-MING ,  HUGUNIN MARGARET ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H ,  LEDDY MARY R

Inventor： HSIEH CHUNG-MING ,  HUGUNIN MARGARET ,  MURTAZA ANWAR ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  PEREZ JENNIFER M ,  ZHONG SUJU ,  TARCSA EDIT ,  CLABBERS ANCA ,  WALLACE CRAIG ,  BRYANT SHAUGHN H ,  LEDDY MARY R

IPC: A61K39/395

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2300/00 ,  C07K16/241 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92

Abstract: Proteins that bind IL- 17 and/or IL- 17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL- 17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Abstract translation: 描述了结合IL-17和/或IL-17F的蛋白以及其在用于治疗，预防和诊断IL-17相关疾病和检测细胞，组织，样品和组合物中的IL-17的组合物和方法中的应用。

公开(公告)号：WO2008082651A2

公开(公告)日：2008-07-10

申请号：PCT/US2007026482

申请日：2007-12-28

Applicant: ABBOTT LAB ,  HSIEH CHUNG-MING ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  ROGUSKA MICHAEL ,  TOMLINSON IAN ,  TUNA MIHRIBAN ,  GRANT STEVEN ,  ENEVER CARRIE

Inventor： HSIEH CHUNG-MING ,  MCRAE BRADFORD L ,  KUTSKOVA YULIYA ,  MEMMOTT JOHN E ,  ROGUSKA MICHAEL ,  TOMLINSON IAN ,  TUNA MIHRIBAN ,  GRANT STEVEN ,  ENEVER CARRIE

IPC: C07K16/24

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/245 ,  C07K2317/569 ,  C07K2317/92

Abstract: The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-l a and human IL-I ß. The dual specific antibodies of the invention also neutralize both human IL-I a and human IC-I ß. The invention also provides domain antibodies (dAbs) specific for human IL-l a and human IL-l ß.

Abstract translation: 本发明提供了对人IL-1α和人IL-1β特异的分离的双重特异性抗体或其抗原结合部分。 本发明的双重特异性抗体还中和人IL-1α和人IC-1β。 本发明还提供对人IL-1α和人IL-1β特异性的结构域抗体（dAb）。

公开(公告)号：WO2008082651A3

公开(公告)日：2008-07-10

申请号：PCT/US2007/026482

申请日：2007-12-28

Applicant: ABBOTT LABORATORIES ,  HSIEH, Chung-ming ,  MCRAE, Bradford, L. ,  KUTSKOVA, Yuliya ,  MEMMOTT, John, E. ,  ROGUSKA, Michael ,  TOMLINSON, Ian ,  TUNA, Mihriban ,  GRANT, Steven ,  ENEVER, Carrie

Inventor： HSIEH, Chung-ming ,  MCRAE, Bradford, L. ,  KUTSKOVA, Yuliya ,  MEMMOTT, John, E. ,  ROGUSKA, Michael ,  TOMLINSON, Ian ,  TUNA, Mihriban ,  GRANT, Steven ,  ENEVER, Carrie

IPC: A61K39/00

Abstract: The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-l α and human IL-I β. The dual specific antibodies of the invention also neutralize both human IL-I α and human IC-I β. The invention also provides domain antibodies (dAbs) specific for human IL-l α and human IL-l β.